Details for Patent: 11,786,508
✉ Email this page to a colleague
Which drugs does patent 11,786,508 protect, and when does it expire?
Patent 11,786,508 protects IGALMI and is included in one NDA.
This patent has twenty-seven patent family members in fourteen countries.
Drugs Protected by US Patent 11,786,508
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioxcel | IGALMI | dexmedetomidine hydrochloride | FILM;BUCCAL, SUBLINGUAL | 215390-001 | Apr 5, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION | ⤷ Try a Trial | ||||
| Bioxcel | IGALMI | dexmedetomidine hydrochloride | FILM;BUCCAL, SUBLINGUAL | 215390-002 | Apr 5, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,786,508
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017388759 | ⤷ Try a Trial | |||
| Australia | 2022200892 | ⤷ Try a Trial | |||
| Brazil | 112019013503 | ⤷ Try a Trial | |||
| Canada | 3045043 | ⤷ Try a Trial | |||
| China | 110337290 | ⤷ Try a Trial | |||
| Eurasian Patent Organization | 201991361 | ⤷ Try a Trial | |||
| European Patent Office | 3562486 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
